Type 2 diabetes patients undergoing metformin treatment experienced reductions in blood glucose and hemoglobin A1C by also taking a novel probiotic product containing certain microbes lacking in diabetes patients, compared with those who received placebo instead of the probiotic product. The small study in BMJ Open Diabetes Research & Care found no major safety or tolerability issues, only transient gastrointestinal symptoms lasting 3 to 5 days, for the novel probiotic product.
Study: New probiotic improves glycemic control in T2D
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.